679
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2−) advanced breast cancer in Kazakhstan

, , , , &
Pages 189-199 | Accepted 22 Sep 2014, Published online: 24 Nov 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Ghader Mohammadnezhad, Melika Sattarpour & Najmeh Moradi. (2022) Budget impact analysis of breast cancer medications: a systematic review. Journal of Pharmaceutical Policy and Practice 15:1.
Read now
Nanxin Li, Yanni Hao, Valerie Koo, Anna Fang, Miranda Peeples, Andrew Kageleiry, Eric Q. Wu & Annie Guérin. (2016) Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2− metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis. Journal of Medical Economics 19:4, pages 414-423.
Read now

Articles from other publishers (3)

Parsa Erfani, Kayleigh Bhangdia, Catherine Stauber, Jean Claude Mugunga, Lydia E. Pace & Temidayo Fadelu. (2021) Economic Evaluations of Breast Cancer Care in Low- and Middle-Income Countries: A Scoping Review. The Oncologist 26:8, pages e1406-e1417.
Crossref
Josephine Mauskopf, Stephanie R. Earnshaw, Anita Brogan, Sorrel Wolowacz & Thor-Henrik BrodtkorbSorrel Wolowacz, Josephine Mauskopf & Stephanie Earnshaw. 2017. Budget-Impact Analysis of Health Care Interventions. Budget-Impact Analysis of Health Care Interventions 11 34 .
Yanni Hao, Nanxin Li, Anna P. Fang, Valerie Koo, Miranda Peeples, Andrew Kageleiry, Eric Q. Wu & Annie Guérin. (2016) Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2− Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. Advances in Therapy 33:6, pages 983-997.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.